Immune treatments for alcohol use disorder: A translational framework
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 97, 349-364
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (F31AA028976, F32AA027699, K24AA025704)
- University of California, Los Angeles (5T32DA024635)
- National Institute on Drug Abuse
This publication has 200 references indexed in Scilit:
- The 2′-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 InhibitorACS Medicinal Chemistry Letters, 2013
- Minocycline reduces ethanol drinkingBrain, Behavior, and Immunity, 2011
- Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated ReceptorsBiological Psychiatry, 2011
- Binge alcohol drinking is associated with GABAAα2-regulated Toll-like receptor 4 (TLR4) expression in the central amygdalaProceedings of the National Academy of Sciences, 2011
- Neurosteroids2010
- Mindfulness-Based Relapse Prevention for Substance Use Disorders: A Pilot Efficacy TrialSubstance Abuse, 2009
- Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugsAlcohol, 2009
- Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in ratsJournal of Hepatology, 2009
- Repeated Lipopolysaccharide (LPS) or Cytokine Treatments Sensitize Ethanol Withdrawal-Induced Anxiety-Like BehaviorNeuropsychopharmacology, 2007
- Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change.Psychology of Addictive Behaviors, 2006